Targeted Antibody Cancer Treatment: Overview of the Revolution
2020 Updates: RSR interviews an antibodies CEO and regularly updates this survey of the field
The mainstream media should be running weekly headlines
updating the public on the latest progress with targeted antibody treatment.
For some reason though, for now, if you want to keep up with the latest astounding
cancer treatment developments, you'll have to keep tuning in to BEL and Real Science Radio!
* How Can This Help a Cancer Patient? (Updated: 3/20/20) Medicine's still in the early years of cancer immunotherapy treatment. So don't assume that your oncologist will know or, knowing, even recommend such. Rather, you can ask your doctor if he knows whether targeted antibody (immunotherapy) treatment and open trials are available for your particular cancer. (And, if you're wealthy, for various reasons, request a full genome sequence of your cancer!) First though, you may want to listen to today's program and carefully read this article!

* Lung Cancer Too: Incredible results should not give false hope to all sufferers, but cautious hope to many. A British media report on a late-stage lung cancer "cure" using antibody treatment (immunotherapy) virtually cured a bedridden hospice patient with advanced lung cancer that has metastasized to his lymph nodes. His oncologist gave this 50-year-old two weeks to live (though such estimates can be notoriously wrong). But two weeks after his antibody treatment with the drug called Opdivo, a drug already available in the U.S., he recovered and returned home, even though previously, his lung cancer already had spread to his vocal cords and lymph nodes. Check out also, "...'remarkable' success fighting end-stage lung cancer in trials, experts say. It is also effective against other cancers" and listen to this report here on BEL.
* Jan 2020 Update: Three papers published together in the journal Nature have added to our targeted antibody arsenal new powerful weapons called B-cells and the in-tumor factories that make them. RSR hopes that with so many major breakthroughs, by 2022, immunotherapy will move to the top of the treatment ladder.
* Feb 2019 Update: Here are two from among the BEL listeners who've had a positive experience asking their oncologists about targeted antibodies. First, Brad H. from Vancouver, BC (kgov.com/brad-2015) called off-air on 2/14/19. His father, who's bladder was removed as its cancer spead to his lymph nodes, had two rounds of chemo with no apparent benefit. Brad thanks BEL for suggesting that patients urge their oncologist to explore immunotherapy. For now, a year after being accepted into a trial, Brad's father appears to be cancer free! Then, RSR listener Tom Healey, 83, passed away after asking for and then receiving an immunotherapy treatment that, while it didn't overcome his deteriorated heath, did enable his own marrow to again produce red blood cells!

* April 2019 Update: More than 1 in 4 go into full remission in small lymphoma immunotherapy trial, now going into larger clinical trial including for breast and head-and-neck cancers. (And see below; this article has been updated throughout 2019!)
* June 2018 Update: Florida woman cured of advanced breast cancer. See the BBC's report on the U.S. National Cancer Institute's amazing success with Judy Perkins, given three months to live and now recovered and still thriving [as of 2019] three years after her cure from the most common form of breast cancer!
* Oct 2018 Update: Two cancer immunotherapy researchers win the 2018 Nobel Prize in Medicine!
* Targeted Antibodies Cancer Treatment Revolution: Among the stunning results for targeted antibodies cancer treatment, CBS News reported on 35 terminally-ill advanced-stage leukemia sufferers. The disease went into remission in 94%, or 33 of 35 patients. Dr. Michael Grossbard, New York University's Perlmutter Cancer Center leukemia specialist told CBS News, "Oncologists are reluctant to use the word extraordinary. But these [results] are extraordinary. These are really remarkable findings..."
* FDA Approval: The FDA has approved Novartis' Kymriah to treat children with acute leukemia. Because various methods of cancer immunotherapy exist, the media and even the FDA itself will claim one or another of these early immunotherapy drugs (see below for those already approved in the U.S.) as a "first". Methods include checkpoint inhibitors and the actual modification of antibodies. See below for more. But first, there's this, right up the street from RSR's studio...
* ArcherDX in Boulder, Colorado: ArcherDX spearheaded the effort to extend the life of 12-year old Zaida. Real Science Radio host Bob Enyart interviews ArcherDX CEO Jason Myers to discuss Zaida's case and to get a better understanding both of this revolution in cancer treatment and of how targeted immunotherapy works. Studies in the U.S. and the U.K. are seeing hundreds of patients with many types of cancer virtually "cured", as some oncologists are now putting it. Not every patient though responds well, and some few have even died from the treatment. Update: Sadly, Zaida herself passed away on March 10, 2017 and while RSR would like to learn the specific cause, of course the family's privacy desires comes first. Overall though, the widespread success is stunning. ArcherDX provides the technology so that a patient's doctor can find out quickly what specific mutations may be causing the cancer. Now, a growing number of oncologists will be offering their patients the greatest of hope through individualized treatment that, like an archer aiming at a target, just might hit the bullseye. Online at ArcherDX.com, this next-generation sequencing (NGS) firm develops what is called target enrichment chemistry.
* Cancers Already Being Successfully Treated: People suffer from more than 100 major types of cancer. And while antibody treatment has resulted in some relatively rare autoimmune or other negative and even lethal side effects, the more common positive treatment experiences range in degree, from significantly extending life expectancy, stopping further tumor growth, and actually shrinking tumors, to major remission, and even to apparent cure. The types of cancer already being successfully treated with immunotherapy, using either the inhibitor or the re-targeting approach, include:
- Lung cancer (non-small cell with 30-50% response rates as of Feb. 2017)
- Childhood leukemia / leukemia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Lymph node cancer
- Melanoma skin cancer (Updates: 2018; 2019)
- Forms of breast cancer (including some success with TNBC)
- Kidney (renal cell) carcinoma (Update: 12/2019)
- Bladder (urothelial) cancer
- Head cancers
- Neck cancers
(Please don't hesitate to email updates to this list to Bob@rsr.org.)
* Targeted Antibodies Trials, Success Stories, News, and RSR Broadcasts: The public awareness of the current revolution in cancer antibody treatment should explode in the 2020s. As with all medicines, patients respond with great variability. However, the following results and ongoing trials are greatly encouraging:
- 2019: Progression-free breast cancer survival improves in a Phase III trial for more than a quarter of the women using antibody drug Margetuximab.
- 2019: Non-small cell lung cancer (NSCLC), the most common type of lung cancer, now in first-ever human trials for a vaccine-type treatment.
- 2019: Late-stage prostate cancer patients in recombinant virus vaccine trial.
- 2019: AI software discovers patterns in lung cancer CT scans that indicate whether a patient is likely or not to benefit from immunotherapy (which is still expensive enough to deplete within a year the life savings of nearly half of patients on it).